{"id":38565,"date":"2026-05-26T10:48:00","date_gmt":"2026-05-26T14:48:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=38565"},"modified":"2026-04-28T08:38:23","modified_gmt":"2026-04-28T12:38:23","slug":"reformulated-drugs-real-money-how-pharma-prices-its-way-past-patent-cliffs","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/reformulated-drugs-real-money-how-pharma-prices-its-way-past-patent-cliffs\/","title":{"rendered":"Reformulated Drugs, Real Money: How Pharma Prices Its Way Past Patent Cliffs"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

The molecule did not change. The price did.<\/p>\n\n\n\n

When AstraZeneca introduced esomeprazole \u2014 branded as Nexium \u2014 in 2001, it was marketing what critics called “purple Prilosec.” The active ingredient was the S-enantiomer of omeprazole, the same compound that had made Prilosec the world’s best-selling drug. The clinical distinction was modest at best. The financial distinction was not. Nexium launched at a price roughly 70% above Prilosec’s, captured the prescriber base before generic omeprazole could land, and generated what one peer-reviewed analysis estimated at $2.36 billion per year in additional spending versus the older formulation [1]. AstraZeneca’s patent on the original compound had already expired. The reformulation gave it a new one.<\/p>\n\n\n\n

That maneuver \u2014 sell the mirror-image molecule, price it like a breakthrough, move the market before the generic arrives \u2014 is not a story about the distant past. It is a template still running at full speed across oncology, metabolic disease, neurology, and rare disease. The tools have become more sophisticated. The regulatory scaffolding has gotten more elaborate. The dollar figures have grown by an order of magnitude. And the pushback \u2014 from antitrust regulators, Medicare negotiators, payer formulary committees, and the occasional federal circuit court \u2014 has grown sharper.<\/p>\n\n\n\n

This article maps how pharmaceutical companies build pricing models around reformulated drugs, what the data says about which approaches actually work, where the legal and regulatory exposure sits in 2026, and what the next five years of the $300 billion patent cliff means for every stakeholder who has a position in this market.<\/p>\n\n\n\n

\n\n\n\n

The Scale of the Problem Payers Are Paying For<\/strong><\/h2>\n\n\n\n

<blockquote> “Removing minor modifications to branded drugs would reduce insurance payments by over $7 billion annually and brand-firm profits by more than $4 billion.” \u2014 Arcidiacono et al., American Economic Journal: Applied Economics [2] <\/blockquote><\/p>\n\n\n\n

That figure is a decade old. The underlying behavior has accelerated. Between 2025 and 2030, more than $300 billion in prescription drug revenues will lose patent exclusivity \u2014 roughly one-sixth of the entire industry’s annual revenue. Nearly 200 drugs will see their patents expire in this window, including about 70 blockbusters generating over $1 billion each in annual sales. The previous cliff, in 2016, eroded about $100 billion in brand-name sales. The current one is three times that size.<\/p>\n\n\n\n

The industry’s response has split into three channels: mergers and acquisitions, pipeline expansion, and lifecycle management. Of the three, lifecycle management through reformulation generates the highest return on invested capital \u2014 often by a factor of ten or more. The FDA’s 505(b)(2) pathway, which authorizes reformulation approvals using existing reference drug data, generated 69 approved reformulations in 2024-2025 alone. That pipeline is materially larger when earlier-stage programs are counted.<\/p>\n\n\n\n

Understanding how those reformulations get priced \u2014 and why payers keep paying \u2014 requires pulling apart a mechanism that operates simultaneously on four levels: regulatory, patent, clinical, and commercial.<\/p>\n\n\n\n

\n\n\n\n

What a ‘Reformulation’ Actually Covers<\/strong><\/h2>\n\n\n\n

The term covers more ground than most payer analysts assume. A reformulation is not simply a different pill shape. It includes \u2014 and courts and regulators have had to rule on each of these categories \u2014 the following:<\/p>\n\n\n\n

Extended-release and modified-release formulations.<\/strong> The same active ingredient, released over a longer time window. Once-daily Namenda XR versus twice-daily Namenda IR. Extended-release methylphenidate versus immediate-release. The clinical story is always the same: adherence, convenience, reduced peak-trough variability. The business story is also always the same: new patent on the delivery mechanism, new regulatory exclusivity period, new Orange Book listing, new automatic-substitution barrier.<\/p>\n\n\n\n

Route-of-administration changes.<\/strong> Intravenous to subcutaneous. Oral to inhaled. Injectable to transdermal. Merck launched Keytruda Qlex, a subcutaneous version of its top-selling cancer immunotherapy, in October 2025 \u2014 delivered under the skin in one to two minutes as opposed to a half-hour infusion. The route change generates a new patent cluster, a new product with distinct Orange Book status, and a clinical narrative about patient convenience that is difficult for formulary committees to dismiss.<\/p>\n\n\n\n

Enantiomeric separation.<\/strong> Taking a racemic mixture and patenting one enantiomer as a “purer” molecule. Prilosec to Nexium is the canonical example. Celexa (citalopram) to Lexapro (escitalopram) is another. The FDA grants three-year marketing exclusivity for new clinical investigations supporting these applications; additional patents on the purified enantiomer extend the commercial wall further.<\/p>\n\n\n\n

Fixed-dose combinations.<\/strong> Combining two already-approved molecules into a single dosage form. Entresto (sacubitril\/valsartan) was listed by CMS as one of the first ten drugs selected for Medicare price negotiation in 2023, with a negotiated Maximum Fair Price disclosed in August 2024, ranging between 38 and 79 percent below 2023 non-federal average manufacturer prices. The combination generated billions in revenue for Novartis precisely because it was priced as an innovation, not as a simple combination of two generics.<\/p>\n\n\n\n

Salt and polymorph changes.<\/strong> Different salt forms of the same active moiety can generate new composition-of-matter patents. Warner Chilcott ran this playbook extensively with Doryx (doxycycline hyclate), product hopping from capsules to tablets to new strengths to tablet-scoring changes.<\/p>\n\n\n\n

Prodrug strategies.<\/strong> Converting an approved drug into a chemical precursor that the body metabolizes into the active compound, generating NCE status and five-year exclusivity. This is among the most aggressive forms of reformulation because it can claim new chemical entity protection even though the pharmacological mechanism is identical to an approved drug.<\/p>\n\n\n\n

Each category carries a different regulatory pathway, a different IP profile, a different litigation risk, and a different pricing ceiling. Getting the interplay right between those variables is what separates a lifecycle management strategy that adds real enterprise value from one that attracts an FTC complaint.<\/p>\n\n\n\n

\n\n\n\n

The Regulatory Infrastructure That Makes This Possible<\/strong><\/h2>\n\n\n\n

The 505(b)(2) Pathway: Pharmaceutical Arbitrage, Codified<\/strong><\/h3>\n\n\n\n

Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act is the statutory basis for most pharmaceutical reformulation strategy. The pathway allows an applicant to file a new drug application that relies, in part, on published literature or on the FDA’s prior finding of safety and effectiveness for a reference listed drug \u2014 without conducting a full clinical trial program from scratch.<\/p>\n\n\n\n

The 505(b)(2) pathway offers a compelling arbitrage opportunity \u2014 leveraging existing safety data to slash development costs by over 90% compared to a full NDA program. A complete Phase I-III clinical development program for a new chemical entity typically runs $1.5 to $2.5 billion over ten to fourteen years. A 505(b)(2) reformulation program, depending on the degree of innovation required, runs $20 million to $200 million over three to seven years. The price ceiling at launch, however, is not proportionally discounted. The manufacturer sets the price based on the clinical differentiation story and the competitive landscape, not on development cost.<\/p>\n\n\n\n

Effective January 1, 2023, CMS began assigning unique, product-specific J-codes to 505(b)(2) products that are not rated as therapeutically equivalent to their reference listed drug in the FDA Orange Book. This seemingly administrative change has profound commercial implications. It means that a reformulated drug rated as “not therapeutically equivalent” cannot be substituted at the pharmacy level for its cheaper reference drug, regardless of what the prescriber intended. It gets billed separately, reimbursed separately, and tracked separately in claims databases \u2014 creating the conditions for premium pricing that payers cannot easily route around through formulary tiering alone.<\/p>\n\n\n\n

From 2003 to 2023, 943 drugs were approved through the 505(b)(2) pathway. With the pathway now lowering submission risks, accelerating development, and providing potential market exclusivity for up to seven years, while also creating a competitive advantage through the ability to request sole-source status, the application volume has been rising consistently.<\/p>\n\n\n\n

Orange Book Listing and Automatic Substitution<\/strong><\/h3>\n\n\n\n

The FDA Orange Book is the list of approved drug products with therapeutic equivalence evaluations. When a drug earns an “AB” rating, pharmacists in most U.S. states can substitute a generic without seeking physician approval. When a drug earns any other rating \u2014 or is not rated at all \u2014 substitution is blocked at the pharmacy counter.<\/p>\n\n\n\n

This rating system is the single most important structural factor in reformulation pricing. A manufacturer who introduces a reformulation that receives a non-AB rating has, in effect, built a wall around the prescriber base that payers can challenge through formulary design but cannot breach through automatic substitution law. The prescriber writes for Nexium; the pharmacist cannot substitute generic omeprazole.<\/p>\n\n\n\n

The FTC has been challenging what it calls “improper Orange Book listings” \u2014 patents listed for devices, packaging, or other features that do not directly claim the active ingredient \u2014 since 2023. The FTC previously challenged many of Ozempic’s patents as improperly listed, in a signal that the era of reflexive listing without scrutiny has ended.<\/p>\n\n\n\n

Patent Term Extensions and the Hatch-Waxman Architecture<\/strong><\/h3>\n\n\n\n

The Drug Price Competition and Patent Term Restoration Act of 1984 \u2014 Hatch-Waxman \u2014 created a framework that was explicitly designed to balance generic competition with brand innovation. The framework gave generic manufacturers a pathway (ANDA, or abbreviated new drug application) to challenge brand patents and gave brand manufacturers a guaranteed 30-month stay when they sued generic challengers.<\/p>\n\n\n\n

What the framers of Hatch-Waxman did not fully anticipate was the degree to which secondary patent filings \u2014 on formulations, delivery mechanisms, metabolites, methods of use, and dosing regimens \u2014 could multiply the number of Orange Book-listed patents on a single drug beyond anything the 30-month stay mechanism was designed to handle.<\/p>\n\n\n\n

AbbVie filed 247 patents on Humira between 2002 and 2023, which successfully delayed U.S. biosimilar competition for years after its primary patent expired, allowing it to generate over $114 billion in revenue since the end of 2016. Sanofi’s insulin product Lantus is associated with 74 patents that collectively protect it from competition for 37 years.<\/p>\n\n\n\n

Those are the extreme examples. But the structure is not unusual. DrugPatentWatch, which tracks patent filings, litigation, and expiry data across the FDA-regulated drug landscape, consistently identifies cases where the secondary patent layer on a reformulated drug exceeds the commercial lifetime of the molecule itself. For any company building a lifecycle management strategy \u2014 or any payer trying to model when generics will actually arrive \u2014 the gap between the compound patent expiry date and the realistic generic entry date is the number that matters, and it is almost always larger than a naive reading of the Orange Book suggests.<\/p>\n\n\n\n

\n\n\n\n

Keytruda Qlex: The $29 Billion Blueprint<\/strong><\/h2>\n\n\n\n

No reformulation strategy announced in the past five years matches the commercial stakes of Merck’s subcutaneous pembrolizumab program.<\/p>\n\n\n\n

Keytruda generated nearly $29 billion in revenue for Merck in 2024 \u2014 already patent-protected in the U.S. until 2028. The intravenous formulation brought in $21.6 billion in income in the first nine months of 2024 alone, representing approximately 45% of the company’s total income. When the IV patents expire and biosimilar challengers enter \u2014 several have active development programs \u2014 Merck faces what analysts have described as an 80% revenue erosion on its flagship product.<\/p>\n\n\n\n

The subcutaneous formulation is the hedge.<\/p>\n\n\n\n

Keytruda Qlex launched in October 2025 and is delivered under the skin in one to two minutes, as opposed to a half-hour infusion. The Phase 3 pivotal study demonstrated non-inferiority to the original IV version, with a 45% overall response rate in non-small cell lung cancer versus 42% for the IV formulation. The trial was accompanied by a switching study in which patients who were given the choice between the two versions after experiencing both showed a preference pattern that Merck’s commercial team will deploy in every payer conversation for the next decade.<\/p>\n\n\n\n

If the subcutaneous version captures 30 to 40% of Keytruda’s existing patient base by 2027 \u2014 Merck’s public target \u2014 the reformulation preserves $9 to $12 billion in annual revenue, generating a return on program investment exceeding 1,000% annually.<\/p>\n\n\n\n

The pricing structure for Keytruda Qlex reflects a calculation that goes beyond simply repricing a biosimilar-proof product. The subcutaneous route creates a genuine clinical advantage for a subset of patients: those with poor venous access, those in settings without infusion capacity, and those for whom the time burden of IV therapy creates adherence problems. That genuine advantage is what separates this reformulation, legally and commercially, from the Namenda XR playbook.<\/p>\n\n\n\n

Merck is not withdrawing IV Keytruda. It is not preventing prescribers from writing for the original. What it is doing \u2014 legally available, commercially rational, and directly analogous to the small-molecule tactics that regulators are increasingly scrutinizing in pill form \u2014 is investing heavily in detailing the new formulation to the prescriber base in the 24-month window before the IV compound patents expire.<\/p>\n\n\n\n

The legal exposure for Merck is lower than it was for Forest\/Actavis with Namenda XR precisely because there is no hard switch. The commercial effectiveness, however, may be similar. Once the oncology prescriber community is writing for Keytruda Qlex \u2014 which carries its own separate patent cluster extending beyond 2028 \u2014 biosimilar challengers to the IV formulation enter a market with a diminishing prescriber base. The reference drug is still technically on the market. But the patients have moved.<\/p>\n\n\n\n

Wall Street analysts expect the subcutaneous version to help significantly offset the looming patent expiration, with one oncologist quoted as saying the launch ‘will extend market share and increase potential revenue over the next five years post-loss of exclusivity.’<\/p>\n\n\n\n

\n\n\n\n

The Namenda Litigation and What It Established<\/strong><\/h2>\n\n\n\n

The Forest Laboratories\/Actavis Namenda case is the most consequential antitrust ruling in the reformulation space in two decades, and its lessons still govern how brand manufacturers structure product-hopping strategies.<\/p>\n\n\n\n

Namenda IR, an immediate-release memantine for Alzheimer’s disease taken twice daily, was generating $1.5 billion per year when Forest introduced Namenda XR \u2014 an extended-release version taken once daily \u2014 and then attempted to withdraw the original IR version from the market, allowing it to enjoy 14 additional years of patent protection.<\/p>\n\n\n\n

Namenda XR was approved by the FDA in 2010 but Actavis chose not to introduce it into the U.S. market until 2013. Then, in late 2014, nine months before patents on IR expired in July 2015, Actavis sought to remove Namenda IR from the market. The New York State Attorney General sued under antitrust laws, and the Court of Appeals for the Second Circuit agreed, ruling that Actavis had to keep Namenda IR on the market.<\/p>\n\n\n\n

The ruling established two principles that now function as the outer boundary conditions for any reformulation strategy:<\/p>\n\n\n\n

First, a brand manufacturer can introduce a new formulation and market it aggressively. That is not, in itself, anticompetitive. The Supreme Court’s precedent on unilateral conduct permits companies to introduce superior products even if they harm competitors.<\/p>\n\n\n\n

Second, combining the introduction of a new product with “hard switch” tactics \u2014 withdrawing the original, declaring it obsolete, or using the regulatory machinery to block automatic substitution \u2014 crosses into potential monopolization territory when the economic rationale for the switch depends entirely on harming generic competition.<\/p>\n\n\n\n

The choice between a soft switch and a hard switch is a risk calculation for the brand manufacturer. The hard switch is more effective at killing generic competition but carries a much higher risk of litigation and regulatory scrutiny. The soft switch is legally safer but may leave a larger residual market for generics to capture.<\/p>\n\n\n\n

Every reformulation strategy built after 2015 has been designed with this binary in mind. The dominant model \u2014 which Merck exemplifies with Keytruda Qlex \u2014 is to pursue the soft switch aggressively enough that the prescriber base migrates on its own, without the legal exposure of a forced withdrawal. The question of whether soft switches themselves can be anticompetitive under sufficiently aggressive conditions remains unsettled in the circuits, which creates ongoing legal risk even for strategies that look legally clean on paper.<\/p>\n\n\n\n

\n\n\n\n

Nexium’s Legacy: The $2.36 Billion-Per-Year Enantiomer<\/strong><\/h2>\n\n\n\n

AstraZeneca’s transition from Prilosec (omeprazole) to Nexium (esomeprazole) is the case study that showed the pharmaceutical industry the full commercial potential of enantiomeric reformulation \u2014 and the one that shaped how every health economist since has measured product-hopping costs.<\/p>\n\n\n\n

An analysis found that AstraZeneca’s efforts to stop generic competition by releasing and encouraging the use of Nexium in the early 2000s cost the healthcare system $2,362.9 million a year.<\/p>\n\n\n\n

The mechanics were specific. Omeprazole’s patent was expiring. Rather than defend Prilosec against generic competition, AstraZeneca isolated the S-enantiomer of omeprazole and filed for a new composition-of-matter patent on esomeprazole. The FDA granted approval under the 505(b)(2) pathway. The Orange Book listing for Nexium did not share an AB rating with generic omeprazole, blocking automatic substitution.<\/p>\n\n\n\n

AstraZeneca then deployed a detailing force with a clinical story \u2014 modestly superior acid suppression in specific subgroups of patients \u2014 while simultaneously offering deeply discounted Nexium to managed care organizations in exchange for preferred formulary placement. The net effect was that prescribers who might have continued writing for Prilosec (where generics could substitute) were writing for Nexium instead, where they could not.<\/p>\n\n\n\n

The follow-on drug \u2014 the brand drug to which an evergreening strategy is applied \u2014 is usually marketed by the pharmaceutical company that owns the brand drug, and both drugs are marketed at the same time in most cases, effectively making them competitors in the same therapeutic category while the older product’s generic erosion is contained to a shrinking prescriber base.<\/p>\n\n\n\n

The Nexium case also illustrates a pricing dynamic that receives less attention than the patent strategy: the role of rebates in creating the illusion of competitive pricing. Nexium’s list price was substantially higher than Prilosec’s. Its net price, after rebates, was often competitive with \u2014 or even below \u2014 the generic omeprazole price for large managed care accounts. The gross-to-net gap allowed AstraZeneca to claim it was competitive on price while extracting substantially higher gross revenue per unit.<\/p>\n\n\n\n

The gross-to-net bubble falls most heavily on patients with high deductibles, whose out-of-pocket costs are calculated against the drug’s WAC price, not the net price after rebates. The Nexium patient paying a percentage copay on a $200 list price was subsidizing the rebate that made Nexium competitive in the commercial formulary negotiation that kept it on Tier 2.<\/p>\n\n\n\n

\n\n\n\n

The GLP-1 Patent Thicket: Ozempic, Rybelsus, and the Architecture of Three Products from One Molecule<\/strong><\/h2>\n\n\n\n

Novo Nordisk’s semaglutide portfolio is the most elaborate example of reformulation-based lifecycle management in the current market. The company has built three commercially distinct products \u2014 Ozempic (injectable, diabetes), Rybelsus (oral tablet, diabetes), and Wegovy (injectable, obesity) \u2014 from a single active molecule, each with its own regulatory approval, indication-specific patent coverage, and pricing architecture.<\/p>\n\n\n\n

Novo Nordisk has filed 320 U.S. patent applications and been granted 154 patents related to these three products. The main compound patent protecting semaglutide as used in these three drugs was set to expire in March 2026, but has been extended by over five years as a result of a Patent Term Adjustment and a Patent Term Extension, to December 2031.<\/p>\n\n\n\n

This extension \u2014 granted for delays during FDA review rather than for any new innovation \u2014 gives Novo Nordisk five additional years of compound-level protection in the United States. Layered on top of that are formulation-specific patents that extend further. Both Wegovy and Rybelsus have patents that will not expire until approximately 2040.<\/p>\n\n\n\n

The pricing architecture across the three products reflects a deliberate segmentation strategy. Rybelsus, the oral formulation, was initially positioned at a premium to Ozempic \u2014 a higher list price justified by the convenience of the oral route and the clinical novelty of an oral GLP-1 agonist. When uptake lagged Ozempic substantially, Novo Nordisk made a branding decision that illustrates how reformulation pricing strategy adapts to market conditions: the FDA accepted “Ozempic” as the proprietary name for the oral semaglutide formulation to address low Rybelsus awareness, with updated U.S. labeling planned for Q2 2026. The science did not change. The brand equity did.<\/p>\n\n\n\n

The litigation layer is active and consequential. Novo Nordisk has already commenced litigation against generics for Wegovy and Rybelsus. Cases against Mylan and Sun Pharmaceuticals remain pending, and a case against Apotex for Rybelsus is also pending. While companies such as Torrent Pharmaceuticals and Dr. Reddy’s Laboratories argue their versions fall “outside the range” of Novo’s patent for the oral formulation Rybelsus, those claims remain untested in court.<\/p>\n\n\n\n

The oral formulation is the key strategic asset in this litigation posture. Generic injectable semaglutide \u2014 which can be compounded under FDA shortage exemptions, as millions of patients discovered during the Ozempic shortage of 2023-2024 \u2014 does not substitute for Rybelsus. The oral-to-injectable AB-rating barrier is absolute. A generic manufacturer who beats the Rybelsus patents will have an oral generic. A generic manufacturer who beats the Ozempic\/Wegovy injectable patents will have an injectable generic. Neither substitutes for the other at the pharmacy counter. Novo Nordisk has structurally separated its two revenue streams, and each stream requires a separate litigation campaign to dismantle.<\/p>\n\n\n\n

I-MAK estimates that the five-year compound patent extension will grant Novo Nordisk an additional $166 billion in revenue that would otherwise not occur if generics entered at the original compound expiry date.<\/p>\n\n\n\n

\n\n\n\n

Pricing Models: What Companies Actually Charge and Why<\/strong><\/h2>\n\n\n\n

The List Price Premium Ladder<\/strong><\/h3>\n\n\n\n

Reformulated drugs almost universally launch at a premium to their reference drugs. The size of that premium follows a consistent pattern based on four variables: degree of clinical differentiation, route-of-administration novelty, indicator of new therapeutic use, and competitive density in the class.<\/p>\n\n\n\n

Route changes command the largest premiums when the original route carries a meaningful burden. Subcutaneous versus intravenous in oncology \u2014 where IV therapy requires infusion center visits, nursing time, pre-medication, and several hours per cycle \u2014 supports premium pricing in the range of 15-40% above the IV reference price. The pricing rationale is partly clinical (fewer adverse events at the infusion site with standardized administration) and partly economic: the healthcare system saves on infusion infrastructure costs, and some of those savings can be captured as a higher drug price.<\/p>\n\n\n\n

Extended-release reformulations in CNS conditions command premiums in the 10-25% range, primarily justified by adherence and once-daily convenience. The challenge is that payers can \u2014 and increasingly do \u2014 respond by placing the brand ER formulation on a higher formulary tier while keeping the generic IR on Tier 1, eroding the premium over time.<\/p>\n\n\n\n

Enantiomeric reformulations command premiums in the 30-100% range, but only for a limited window. Once prescribers and payers accumulate real-world evidence that the enantiomeric product delivers no material clinical benefit over the generic racemate, the formulary pressure becomes severe.<\/p>\n\n\n\n

The Net Price Reality<\/strong><\/h3>\n\n\n\n

Every list price in the pharmaceutical market is a fiction used for one purpose only: calculating rebate leverage. The net price \u2014 what payers actually pay after manufacturer rebates, distributor fees, and patient assistance program offsets \u2014 is the real economic unit.<\/p>\n\n\n\n

For reformulated drugs, the gross-to-net gap is often larger than for the brand original drug, because the reformulation is entering a market where the payer already has a cheaper reference product and will demand substantial rebates to grant preferred formulary placement.<\/p>\n\n\n\n

The pharmaceutical delivery supply chain depends on a payment system where manufacturers set pharmaceutical prices and payers strive to obtain discounts and prices that are fair for the expected value of the product. For reformulations, “expected value” is a contested concept. The manufacturer’s HEOR (health economics and outcomes research) team will argue that adherence benefits, reduced administration costs, and superior patient outcomes justify the premium. The payer’s pharmacy team will argue that the clinical benefit is marginal and the reference drug will do.<\/p>\n\n\n\n

The outcome of that negotiation \u2014 the formulary tier placement, the prior authorization criteria, the step-therapy requirement \u2014 determines whether the reformulation’s list price premium translates into net revenue or evaporates in the rebate stack.<\/p>\n\n\n\n

The 505(b)(2) Sole-Source Advantage in Medicare Part B<\/strong><\/h3>\n\n\n\n

The 2022 CMS policy shift \u2014 under which 505(b)(2) products not rated as therapeutically equivalent to their reference listed drug are assigned unique J-codes and treated as sole-source drugs \u2014 has profound strategic implications for oncology and hospital-administered drugs billed under Medicare Part B.<\/p>\n\n\n\n

Medicare Part B reimburses physician-administered drugs at ASP (Average Selling Price) plus 6%. For a sole-source drug, there is no generic ASP to compete against. The manufacturer’s ASP is the only ASP. This means a 505(b)(2) oncology drug with a non-AB Orange Book rating can maintain its pricing without the downward pressure that generic ASP competition creates for Part B drugs.<\/p>\n\n\n\n

Infusion centers and oncology practices, meanwhile, have an operational incentive to use these sole-source formulations: the 6% add-on generates more margin on a higher-priced drug. For oncology pharmacists, understanding the 505(b)(2) approval pathway and its implications is necessary to effectively navigate the challenges 505(b)(2) drugs are creating for infusion center pharmacies. The challenges cut both ways: sole-source designations create revenue opportunities for infusion centers but also create billing complexity and compliance risk if the J-code taxonomy is not properly tracked.<\/p>\n\n\n\n

\n\n\n\n

The IRA Variable: How Medicare Negotiation Changes the Reformulation Calculus<\/strong><\/h2>\n\n\n\n

The Inflation Reduction Act’s drug price negotiation authority, which first applied to ten drugs in 2024-2025, has introduced a new variable into reformulation strategy that the industry has not yet fully priced into its pipeline decisions.<\/p>\n\n\n\n

The IRA cannot address the high launch prices of new drugs, which are exempt from negotiation for their first nine years on the market. This has incentivized manufacturers to set aggressive initial prices to maximize revenue before negotiation becomes a factor.<\/p>\n\n\n\n

For reformulated drugs, this creates a specific strategic decision point. A reformulation approved via 505(b)(2) with a new NDA number starts its nine-year small-molecule negotiation clock from the date of the new approval \u2014 not from the original drug’s approval date. This means a reformulation launched in 2025 would not face negotiation pressure until 2034 at the earliest, even if the reference drug’s negotiation clock is already running.<\/p>\n\n\n\n

The IRA’s Medicare negotiation authority changes the incentive calculation for reformulation in a specific and underappreciated way. Companies with drugs approaching the Medicare negotiation selection threshold \u2014 high Part D spending, old enough to be eligible \u2014 have a structural incentive to transition patient volume to a reformulation with a new NDA number, restarting the negotiation clock while maintaining therapeutic continuity.<\/p>\n\n\n\n

This dynamic is already visible in the Keytruda situation. The IV formulation of pembrolizumab faces biosimilar entry around 2028 and would ultimately face potential negotiation pressure in subsequent rounds. Keytruda Qlex, as a new NDA product with its own approval date, is a distinct product under IRA mechanics. The first round of negotiated drugs was announced in August 2023, including Eliquis, Jardiance, Xarelto, Enbrel, Imbruvica, Januvia, Entresto, Farxiga, Stelara, and Fiasp\/NovoLog insulin formulations. None of them were reformulations that had entered their exclusivity windows in the preceding nine years.<\/p>\n\n\n\n

The IRA’s nine-year exclusivity carve-out is, in effect, a reformulation subsidy. Every dollar invested in a 505(b)(2) reformulation that earns a new NDA number buys at least nine years of freedom from Medicare negotiation, regardless of the reference drug’s age.<\/p>\n\n\n\n

The program is set to expand, with an additional fifteen drugs selected for negotiation for 2027, and a third cycle of drugs announced in January 2026 for prices effective in 2028. As the list grows and more therapeutic categories come into scope, the reformulation clock-reset strategy will become increasingly valuable for drugs in the later stages of their primary exclusivity periods.<\/p>\n\n\n\n

\n\n\n\n

The Suboxone Case: When ‘Safety’ Arguments Cover Commercial Motives<\/strong><\/h2>\n\n\n\n

If Namenda established the hard-switch boundary and Nexium established the enantiomer playbook, Suboxone established a third pattern: using a safety argument \u2014 specifically, child safety \u2014 to justify a product transition that happens to have the effect of blocking generic competition.<\/p>\n\n\n\n

Reckitt Benckiser’s Suboxone transition from tablet to sublingual film is documented in detail in federal litigation records. The film formulation had genuine advantages: faster onset, reduced potential for diversion, and \u2014 the argument that proved most contentious \u2014 reduced risk of accidental pediatric exposure.<\/p>\n\n\n\n

The Suboxone case involved a hard switch that was later challenged in court as illegal market monopolization. Courts stated that ‘simply introducing a new product on the market, whether it is a superior product or not, does not, by itself, constitute exclusionary conduct,’ but found the focus of analysis should be on ‘whether the defendant combined the introduction of a new product with some other wrongful conduct, such that the comprehensive effect is likely to stymie competition.’<\/p>\n\n\n\n

Reckitt filed citizen petitions with the FDA raising safety concerns about the tablet formulation \u2014 concerns that, according to the State of Kentucky’s antitrust complaint, Reckitt’s own internal documents showed were not the primary driver of the product transition. The company also sent letters to state Medicaid programs and prescribers flagging the safety concerns, which had the effect of accelerating the prescriber base migration to film before generics could enter.<\/p>\n\n\n\n

The Suboxone litigation illustrates a risk that every reformulation team should understand: internal communications are discoverable in antitrust litigation. Emails that discuss the competitive implications of a product transition while the external communication emphasizes clinical rationale create evidentiary problems that are difficult to argue around. The FTC and state attorneys general have become sophisticated at identifying the gap between the public clinical narrative and the private commercial narrative.<\/p>\n\n\n\n

\n\n\n\n

TriCor and the Cholesterol Drug Playbook: Abbott’s Serial Reformulation<\/strong><\/h2>\n\n\n\n

Abbott’s management of its fenofibrate franchise \u2014 TriCor \u2014 is a case study in serial reformulation designed specifically to stay ahead of generic equivalents through continuous dose and formulation changes.<\/p>\n\n\n\n

Abbott stymied generic competition for TriCor by switching the official version from a capsule to a tablet, changing the dose, and discontinuing the capsules, in order to block the generic versions which were meant to substitute for the capsules.<\/p>\n\n\n\n

The strategy ran through multiple iterations. When the capsule patent was challenged, Abbott introduced a tablet at a different dose strength. When generics filed for the tablet, Abbott changed the tablet scoring. When generics matched that, Abbott introduced a new formulation at yet another dose with a different clinical argument. Each transition required generic manufacturers to restart their ANDA filing \u2014 matching the new reference product rather than the old one that their formulation had been designed to replicate.<\/p>\n\n\n\n

The economic result: patients who had been taking TriCor were continuously migrated to the newest formulation before generics could enter the market for the previous version. By the time a generic for the capsule was finally approved, most prescribers had been detailing onto the tablet for two years. The generic launched into a market where the primary drug had already changed.<\/p>\n\n\n\n

The brand-name drug company takes advantage of its market power to shift pharmacists, doctors, and consumers to new versions of drugs before a generic for the ‘old’ version is able to reach the market. TriCor is the clearest example of this tactic run through multiple product iterations rather than a single transition.<\/p>\n\n\n\n

For brand manufacturers looking at TriCor as a template, the relevant lesson is not the specific tactics \u2014 courts and the FTC have both signaled those specific patterns attract scrutiny \u2014 but the underlying principle: the earlier the prescriber migration begins relative to generic entry, the smaller the commercial opportunity the generic captures when it finally arrives.<\/p>\n\n\n\n

\n\n\n\n

How Payers Are Getting Smarter<\/strong><\/h2>\n\n\n\n

The payer response to reformulation pricing strategy has evolved substantially in the past five years. Several tactics that worked reliably in 2015 are now generating pushback that materially affects net price.<\/p>\n\n\n\n

Formulary exclusion of reformulations without meaningful clinical differentiation.<\/strong> Express Scripts, CVS Caremark, and OptumRx have all updated their formulary exclusion lists to include branded reformulations where the reference drug with generic availability is therapeutically equivalent for the indicated population. The bar for what counts as “meaningful clinical differentiation” has risen: convenience-only arguments increasingly result in non-preferred or excluded status.<\/p>\n\n\n\n

Step therapy requirements targeting reformulations.<\/strong> Before a patient can access a reformulated brand drug, many commercial plans now require documented failure on (or contraindication to) the generic reference drug. For ER formulations in conditions where the IR generic is adequate for the majority of patients, this step therapy requirement substantially limits the reformulated product’s effective prescribable population.<\/p>\n\n\n\n

Real-world evidence requirements.<\/strong> Payers are increasingly requiring post-approval real-world evidence studies as conditions for preferred formulary placement. A reformulation that earns preferred status on clinical trial data must demonstrate in the real-world patient population that the adherence or safety benefits translate into outcomes differences that justify the price premium. This creates ongoing commercial risk for reformulations whose trials were designed with careful patient selection that may not reflect the broader commercial population.<\/p>\n\n\n\n

Outcomes-based contracts.<\/strong> Pharmaceutical payment models are negotiated throughout the pharmaceutical supply chain, and value-based or outcomes-based contracting is the fastest-growing segment of that negotiation landscape. For reformulations, outcomes-based contracts have a specific appeal for payers: if the manufacturer is confident in the adherence benefits, it should be willing to tie part of its rebate to demonstrated adherence improvements in the covered population. Manufacturers who accept these contracts signal genuine clinical confidence; those who resist signal that the clinical story may not hold up in practice.<\/p>\n\n\n\n

\n\n\n\n

The FTC’s Escalating Scrutiny<\/strong><\/h2>\n\n\n\n

In 2022, the U.S. Federal Trade Commission sued AbbVie over Humira’s patent strategy, calling it an illegal monopoly. That case is part of a broader escalation in antitrust enforcement targeting pharmaceutical lifecycle management practices.<\/p>\n\n\n\n

The FTC’s 2024 report on pharmacy benefit managers found that vertically integrated PBMs engage in practices that inflate drug costs and disadvantage independent pharmacies. State-level action has been more rapid: multiple states passed PBM transparency and spread pricing prohibition legislation between 2023 and 2025, requiring PBMs operating in their markets to disclose rebate retention rates and prohibiting profit-taking on the spread between plan charges and pharmacy reimbursement.<\/p>\n\n\n\n

The European Medicines Agency has taken a different approach. The European Medicines Agency now requires proof of “significant clinical benefit” before granting extra exclusivity for reformulations. This standard \u2014 which does not exist in the United States FDA framework \u2014 creates a regulatory bifurcation: a reformulation that earns three-year marketing exclusivity in the U.S. on the basis of adequate clinical investigation may not earn any exclusivity extension in the EU without demonstrating that it is materially better for patients.<\/p>\n\n\n\n

For companies with global ambitions, this bifurcation requires dual pricing and dual clinical strategies. The U.S. clinical package designed to satisfy FDA’s 505(b)(2) requirements may not be sufficient to satisfy EMA’s “significant clinical benefit” bar. Running separate clinical programs for the two markets \u2014 or selecting indications and patient populations where the benefit can be demonstrated more clearly \u2014 adds cost to reformulation programs that affects the net ROI calculation.<\/p>\n\n\n\n

\n\n\n\n

Patent Cliff Response: The $300 Billion Imperative<\/strong><\/h2>\n\n\n\n

Between 2025 and 2030, five of the top ten pharma companies face 50% or more revenue exposure from loss of exclusivity. The previous patent cliff, in 2016, eroded about $100 billion in brand-name sales. The current one is three times that size.<\/p>\n\n\n\n

The companies in the most acute position:<\/p>\n\n\n\n

Merck faces the Keytruda cliff. Its response \u2014 Keytruda Qlex plus pipeline expansion in immunology and cardiometabolic disease \u2014 is the most clearly executed lifecycle management strategy in the current market.<\/p>\n\n\n\n

Bristol-Myers Squibb faces what analysts describe as the steepest proportional cliff, with approximately 47% of revenues at risk by 2030. Eliquis ($13 billion) and Opdivo ($9 billion) together represent about 45% of total revenues. The Opdivo situation is particularly complex: a subcutaneous formulation of nivolumab was approved in 2024, mirroring the Keytruda Qlex strategy, but Opdivo’s market share position in PD-1 oncology is weaker than Keytruda’s, limiting the switching potential.<\/p>\n\n\n\n

AstraZeneca’s response has been more aggressive on the acquisition side than on the reformulation side, though its respiratory franchise has benefited from combination-product strategies that blend formulation novelty with new device IP.<\/p>\n\n\n\n

Novo Nordisk’s semaglutide architecture \u2014 three products from one molecule, with patent protection extending to 2040 on the oral formulation \u2014 is the most comprehensive reformulation defense of any major asset in the industry.<\/p>\n\n\n\n

New delivery routes, dosage forms, and excipient combinations each generate fresh IP and market exclusivity, making reformulation the highest-ROI response to the cliff.<\/p>\n\n\n\n

\n\n\n\n

DrugPatentWatch and the Intelligence Imperative<\/strong><\/h2>\n\n\n\n

For any company building a reformulation strategy \u2014 or any payer, generic manufacturer, or investor trying to assess one \u2014 the quality of patent intelligence is a direct input into the quality of the commercial decision.<\/p>\n\n\n\n

The gap between what the Orange Book shows and what actually protects a drug commercially is the central intelligence problem in pharmaceutical lifecycle management. The Orange Book lists patents. It does not tell you which patents are vulnerable to invalidity challenges, which were filed with formulation claims broad enough to block a competitor’s reformulation, or which are the product of improper listing that the FTC might challenge.<\/p>\n\n\n\n

Platforms like DrugPatentWatch have become essential for 505(b)(2) reference listed drug selection and timing. Beyond the Orange Book, the FDA’s Orange Book lists patents but doesn’t tell you if they are vulnerable. For a 505(b)(2) developer, selecting the right reference listed drug \u2014 one whose patents are either weak, near expiry, or susceptible to design-around \u2014 is the foundational decision that determines the entire commercial timeline and IP risk profile of the reformulation.<\/p>\n\n\n\n

DrugPatentWatch aggregates patent filing data, litigation outcomes, Paragraph IV certification histories, and regulatory exclusivity timelines across the FDA-approved drug landscape. For a reformulation team, this data answers questions that cannot be answered from the Orange Book alone: Has any company previously filed a Paragraph IV certification against this patent? What was the outcome? Are there related patents in the same family that weren’t listed but could still block a generic reformulation? Has the patent been reexamined or subjected to an IPR proceeding?<\/p>\n\n\n\n

For payers negotiating with a manufacturer who is defending a reformulation’s price on the basis of strong IP protection, this data provides the counter-argument: the IP protection is X years, not the manufacturer’s claimed Y years, and generic entry probability within the plan’s three-year formulary horizon is materially higher than the manufacturer’s commercial team suggests.<\/p>\n\n\n\n

The pricing power of a reformulation is, in part, a function of how long payers believe they will have no generic alternative. Payers who invest in patent intelligence \u2014 directly or through intermediaries like DrugPatentWatch \u2014 price that duration more accurately, which gives them leverage in rebate negotiations that payers relying only on manufacturer-provided information do not have.<\/p>\n\n\n\n

\n\n\n\n

Strategic Framework: Four Reformulation Pricing Models<\/strong><\/h2>\n\n\n\n

After examining the case law, the regulatory landscape, and the commercial outcomes across two decades of reformulation strategies, four distinct pricing models emerge. Each reflects a different clinical reality, a different IP posture, and a different relationship with payers.<\/p>\n\n\n\n

Model 1: The Clinical Premium<\/strong><\/h3>\n\n\n\n

This model applies to reformulations with genuine, demonstrated clinical differentiation \u2014 typically in patient subpopulations where the original formulation creates measurable problems.<\/p>\n\n\n\n

The clinical premium is supported by head-to-head trial data (not just vs. placebo), pre-specified patient-reported outcome endpoints, and a HEOR model that translates clinical benefit into payer-relevant cost offsets. The Keytruda Qlex switching trial \u2014 where patients expressed a preference for the subcutaneous formulation after experiencing both \u2014 is an example of the kind of evidence that supports a clinical premium argument.<\/p>\n\n\n\n

Price point: 15-35% above the reference drug’s net price, negotiated down from a 30-50% list price premium. Market access: preferred formulary positioning achievable in commercial plans; step therapy may apply but can be defeated with the clinical evidence. Litigation risk: low, provided the hard switch is avoided.<\/p>\n\n\n\n

Model 2: The Convenience Premium<\/strong><\/h3>\n\n\n\n

This model applies to reformulations where the differentiation is primarily convenience-based \u2014 once-daily versus twice-daily dosing, oral versus injectable \u2014 without strong head-to-head clinical outcome data.<\/p>\n\n\n\n

The convenience premium is harder to defend because payers have learned to code for it. Formulary exclusion lists increasingly target convenience-only reformulations. The commercial window for a convenience premium is shrinking: when the reference generic is on Tier 1 and the reformulation is on Tier 3 with a prior authorization, the convenience story has to be compelling enough that prescribers fight the authorization battle.<\/p>\n\n\n\n

Price point: 10-20% above net price. Market access: non-preferred in most commercial plans, often with step therapy. Litigation risk: moderate if combined with any hard-switch elements.<\/p>\n\n\n\n

Model 3: The Segmentation Play<\/strong><\/h3>\n\n\n\n

This model \u2014 which Novo Nordisk has executed most comprehensively with semaglutide \u2014 involves creating multiple products from a single molecule, each targeting a distinct patient segment and priced differently.<\/p>\n\n\n\n

Rybelsus captures patients who refuse or cannot receive injections. Wegovy captures the obesity indication with its own separate pricing that reflects willingness to pay among the commercially insured population and, increasingly, employer plan sponsors. Ozempic serves the diabetes core market. Each product has its own formulary dynamic, its own clinical evidence, and its own negotiating relationship with payers. The segmentation creates pricing floors: a payer who wants access to the oral formulation negotiates separately from the one who wants access to the obesity indication.<\/p>\n\n\n\n

Price point: variable by segment and indication. Market access: highly dependent on indication coverage policy. Litigation risk: low on the product structure itself; moderate on the patent thicket claims.<\/p>\n\n\n\n

Model 4: The Clock Reset<\/strong><\/h3>\n\n\n\n

This model is explicitly IRA-driven and will become more prevalent as the negotiation program expands to more drugs annually.<\/p>\n\n\n\n

A manufacturer whose product is approaching Medicare negotiation eligibility \u2014 high Part D spending, small-molecule drug approaching its ninth year post-approval \u2014 invests in a reformulation that earns a new NDA number and a new nine-year exclusivity clock. The reformulation does not need to be clinically transformative. It needs to be differentiated enough to earn a non-AB Orange Book rating, which prevents pharmacists from substituting the reference drug when the new formulation is prescribed.<\/p>\n\n\n\n

Price point: parity or modest premium to the reference drug. The goal is not to maximize the price of the reformulation but to restart the IRA clock. Market access: achievable if the price is set at or near reference net price. Litigation risk: low if done correctly. FTC risk: moderate if the reformulation is accompanied by any supply disruption of the reference drug.<\/p>\n\n\n\n

\n\n\n\n

The European Contrast: Where ‘Significant Clinical Benefit’ Is Non-Negotiable<\/strong><\/h2>\n\n\n\n

The European regulatory and pricing environment for reformulations is materially stricter than the U.S. environment in ways that constrain strategy for companies with global ambitions.<\/p>\n\n\n\n

The European Parliament’s Pharmaceutical Proposal, adopted in April 2024, is designed to create a single market for medicines and to reform exclusivity policies to increase R&D incentives. Under the proposal, additional market exclusivity for reformulations requires a demonstration of “significant clinical benefit” \u2014 a standard that does not require only non-inferiority to the original formulation but genuine incremental therapeutic value.<\/p>\n\n\n\n

Under EU health technology assessment (HTA) frameworks, reformulations that claim convenience benefits alone receive “no added benefit” ratings \u2014 the lowest HTA classification \u2014 which translates into reference pricing based on the original drug’s price rather than a premium. A company that prices a subcutaneous reformulation at 30% above the IV reference price in the U.S. will find that the same premium is not available in Germany, France, or the United Kingdom without head-to-head data demonstrating superiority on a meaningful clinical endpoint.<\/p>\n\n\n\n

This regulatory constraint actually shapes the clinical evidence generation strategy for reformulation programs with global ambitions. Companies who want both U.S. and EU pricing power must design their pivotal trials with endpoints that can support HTA submissions \u2014 which means outcome endpoints, not just PK bridging or non-inferiority on surrogate markers. The additional clinical investment required narrows the ROI advantage of 505(b)(2) reformulation versus full NCE development in Europe, even as it remains compelling in the U.S.<\/p>\n\n\n\n

\n\n\n\n

The Compounding Threat: What the GLP-1 Shortage Revealed<\/strong><\/h2>\n\n\n\n

The 2023-2024 semaglutide shortage, which led the FDA to allow compounding pharmacies to produce semaglutide under the shortage exemption, created an unplanned experiment in what happens when a reformulation’s pricing power is suspended by the supply chain.<\/p>\n\n\n\n

Compounded semaglutide \u2014 produced at dramatically lower cost than Novo Nordisk’s branded products \u2014 captured an estimated 40% of prescriptions in some therapeutic segments during the peak shortage period. Patients and physicians who had never considered a generic or compounded alternative discovered that the molecule’s efficacy, at a fraction of the price, was clinically acceptable.<\/p>\n\n\n\n

The FDA’s decision in early 2025 to end the shortage designation for semaglutide \u2014 and therefore end the legal basis for compounding \u2014 was contested by compounding pharmacies who argued that demand still substantially exceeded supply. The legal status remained in flux through mid-2025.<\/p>\n\n\n\n

What the episode demonstrated is that when a reformulation’s pricing power depends on a combination of IP protection and supply scarcity, the supply scarcity component is fragile. A shortage that activates compounding exemptions can substitute for the branded product in ways that permanent generic entry cannot, at least in the short term. Novo Nordisk’s response \u2014 betting that aggressive price cuts, including a 48% reduction for the starting dose of Wegovy, will blunt generic competition by trading margins for volume \u2014 is a direct response to what the compounding episode revealed about price elasticity in the GLP-1 market.<\/p>\n\n\n\n

\n\n\n\n

What Biosimilars Teach the Small-Molecule Reformulation Market<\/strong><\/h2>\n\n\n\n

The biosimilar market provides a preview of how the biologics reformulation game plays out over longer time horizons \u2014 and the lessons are instructive for small-molecule manufacturers.<\/p>\n\n\n\n

When Humira generics finally arrived in 2023, prices dropped by more than 80%. But the first U.S. biosimilar approval came in 2016. The seven years between first approval and actual meaningful market entry represents the most successful patent thicket defense in pharmaceutical history \u2014 and it was built almost entirely from secondary patents on formulations, concentrations, devices, and administration methods.<\/p>\n\n\n\n

AbbVie’s approach to Humira generated the clearest illustration of what maximum-effort reformulation and patent filing can achieve. The company did not rely on a single reformulation. It built a portfolio of formulation patents covering every concentration, every delivery device, every administration method, and every preservative system used in the product. Generic manufacturers who wanted to enter had to either challenge all of them simultaneously or design around all of them \u2014 a commercial and legal undertaking that most potential challengers could not sustain.<\/p>\n\n\n\n

The FTC has cited the Humira patent thicket in its escalating campaign against Orange Book listing abuse. In 2022, the FTC sued AbbVie over Humira’s patent strategy, calling it an illegal monopoly. The case remains in litigation. Whatever its outcome, the Humira playbook \u2014 accumulating hundreds of secondary patents and listing as many as possible in the Orange Book \u2014 is under explicit regulatory pressure in a way it was not before 2020.<\/p>\n\n\n\n

For small-molecule reformulation strategy, the Humira case suggests that the tolerance for secondary patent accumulation as a blocking strategy is declining. The FTC’s willingness to challenge the entire Humira patent estate \u2014 not just one or two specific listings \u2014 signals that mass-filing strategies are now litigation targets rather than safe harbors.<\/p>\n\n\n\n

\n\n\n\n

Practical Implications for Each Market Participant<\/strong><\/h2>\n\n\n\n

For Brand Manufacturers Building Lifecycle Strategies<\/strong><\/h3>\n\n\n\n

The commercial case for reformulation remains strong, but the regulatory and litigation environment has raised the bar. Four things have changed since 2015:<\/p>\n\n\n\n

The IRA’s nine-year negotiation exemption is now explicitly part of the ROI calculation for reformulation investment. Programs that restart the negotiation clock on high-Part-D-spend assets need to be in the pipeline now, because the clinical development timeline means that decisions made in 2025 determine the commercial positioning in 2030.<\/p>\n\n\n\n

The FTC’s Orange Book challenge program \u2014 which sent letters to more than 100 companies in 2023 questioning specific patent listings \u2014 means that Orange Book listing strategies need legal review that is more rigorous than the traditional approach of listing any patent that arguably covers any feature of the product.<\/p>\n\n\n\n

The EMA’s “significant clinical benefit” requirement means that reformulation programs with global ambitions need clinical designs that can satisfy EU HTA requirements \u2014 which means outcome endpoints and, ideally, head-to-head data.<\/p>\n\n\n\n

The Namenda ruling means that the hard switch is effectively off the table as a commercial strategy. Soft switches remain available but must be structured carefully to avoid the “combined with other wrongful conduct” liability theory that the Second Circuit identified.<\/p>\n\n\n\n

For Generic Manufacturers Targeting Reformulations<\/strong><\/h3>\n\n\n\n

The 505(b)(2) pathway cuts both ways. A generic company that files a 505(b)(2) application for its own reformulation of an off-patent drug can earn three-year marketing exclusivity and a non-AB rating \u2014 becoming, in effect, a sole-source drug itself for the duration of that exclusivity.<\/p>\n\n\n\n

Platforms like DrugPatentWatch have become essential for reference listed drug selection and timing. For a generic company, identifying the reformulations whose patent clusters are weakest \u2014 or whose Orange Book listings are most vulnerable to FTC challenge \u2014 is the first step in a rational litigation strategy.<\/p>\n\n\n\n

Paragraph IV certifications against reformulation patents succeed at higher rates when the reformulation patents are on delivery systems or devices rather than on the active ingredient itself. Post-Alice patent eligibility challenges can be particularly effective against method-of-administration patents that claim what amounts to an abstract idea implemented through routine drug delivery.<\/p>\n\n\n\n

For Payers Managing Formularies<\/strong><\/h3>\n\n\n\n

The 2023 CMS policy change on 505(b)(2) J-codes means that the universe of sole-source drugs in the Medicare Part B formulary is larger than it was two years ago, and it is growing. Payers who rely on generic substitution at the pharmacy counter to manage costs on reformulated drugs need to update their formulary management frameworks to account for the non-AB rating as a permanent feature of the landscape rather than an anomaly.<\/p>\n\n\n\n

Prior authorization and step therapy remain the most effective tools for managing reformulation pricing power in commercial plans. The clinical evidence requirements for step therapy should be designed to match the actual evidence base for the reformulation \u2014 if the reformulation’s clinical advantage is only demonstrated in a specific subpopulation, the step therapy criteria should be calibrated to that subpopulation, not applied across all users of the therapeutic class.<\/p>\n\n\n\n

Outcomes-based contracting is underutilized in the reformulation space. Manufacturers who believe in their adherence and outcomes stories should, in principle, be willing to accept contracts that tie rebate levels to demonstrated performance. Payers who push for these contracts will either get them \u2014 confirming the manufacturer’s clinical confidence \u2014 or not get them, which tells them something important about the evidentiary quality of the reformulation’s value story.<\/p>\n\n\n\n

\n\n\n\n

The Next Five Years: Where Reformulation Pricing Goes From Here<\/strong><\/h2>\n\n\n\n

Three forces are simultaneously reshaping the reformulation pricing landscape in ways that will determine the commercial viability of each of the four models described above.<\/p>\n\n\n\n

The IRA negotiation expansion.<\/strong> As more drugs enter Medicare negotiation annually, the pool of assets where the clock-reset reformulation makes economic sense will grow. Manufacturers with drugs approaching nine years of market age and high Medicare Part D spending are building reformulation programs specifically to exploit the negotiation exemption. The IRA creates a perverse but commercially rational incentive to invest in 505(b)(2) reformulations that would not otherwise clear the investment hurdle.<\/p>\n\n\n\n

The FTC’s evolving enforcement posture.<\/strong> The FTC has moved from case-specific intervention (Namenda, Suboxone) to systematic Orange Book challenge programs. The next phase of enforcement is likely to target the soft switch more directly \u2014 specifically, the detailing and prescriber marketing practices that accelerate patient migration to reformulations in the run-up to generic entry. If courts accept the FTC’s theory that systematic soft-switch marketing campaigns, combined with patent filings designed to create non-AB ratings, constitute anticompetitive conduct, the legal risk profile of the convenience-premium and segmentation-play models rises substantially.<\/p>\n\n\n\n

The biosimilar market maturation model for biologics.<\/strong> The delayed but ultimately dramatic price compression that followed Humira biosimilar entry provides the most relevant precedent for how the Keytruda Qlex situation will resolve over a ten-year horizon. If biosimilar pembrolizumab enters around 2028 at meaningful discounts to the IV reference price, the pressure on Keytruda Qlex’s pricing will build through payer formulary management even without automatic substitution, as payers create strong financial incentives for prescribers to use biosimilar IV pembrolizumab where clinically appropriate. The subcutaneous formulation’s premium will be sustainable only in patient segments where the IV route is genuinely inferior.<\/p>\n\n\n\n

The twin pressures of Medicare negotiation and most-favored-nation pricing have broken a decades-long pricing consensus that allowed U.S. pharmaceutical prices to substantially exceed prices in other developed markets. Reformulation strategy operates within that breaking consensus \u2014 and the strategies that will remain commercially viable in 2030 are the ones whose clinical differentiation is real enough to survive payer scrutiny in a market that has far less tolerance for price premiums than it did a decade ago.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways<\/strong><\/h2>\n\n\n\n

Reformulation strategy is not a single tactic \u2014 it is a matrix of decisions.<\/strong> The optimal path depends on the regulatory pathway (505(b)(2) versus full NDA), the IP posture (composition-of-matter versus formulation versus device patents), the clinical evidence base (non-inferiority versus superiority versus patient preference), and the commercial environment (IRA exposure, competitive density, payer sophistication).<\/p>\n\n\n\n

The 505(b)(2) pathway is the primary regulatory engine for reformulation pricing power.<\/strong> The 2023 CMS policy change creating unique J-codes for non-therapeutically equivalent 505(b)(2) products has made the pathway significantly more valuable for drugs administered in clinical settings under Medicare Part B. Any company building a reformulation strategy for an injectable or infused drug should begin with an analysis of Orange Book rating implications.<\/p>\n\n\n\n

The IRA’s nine-year negotiation exemption is now a reformulation incentive.<\/strong> Drugs approaching Medicare negotiation eligibility \u2014 high Part D spending, approaching nine years post-approval \u2014 are candidates for reformulation programs specifically designed to restart the negotiation clock. This incentive will become more commercially significant as the annual list of negotiated drugs grows.<\/p>\n\n\n\n

The clinical evidence bar is rising, globally.<\/strong> U.S. FDA approval of a 505(b)(2) reformulation on non-inferiority data is achievable. European HTA approval of a premium price on the same data is not. Companies building global reformulation programs need clinical designs that satisfy both standards from the outset.<\/p>\n\n\n\n

Hard switches are legally untenable; soft switches require careful design.<\/strong> The Namenda precedent bars withdrawal of the original formulation as a mechanism for forcing patient migration. Aggressive soft-switch marketing campaigns may face escalating FTC scrutiny if the combined effect is demonstrably to block generic competition. The commercially optimal approach \u2014 exemplified by Keytruda Qlex \u2014 is clinical differentiation clear enough that prescribers migrate voluntarily, without detailing campaigns that raise anticompetitive inference.<\/p>\n\n\n\n

Patent intelligence is a commercial input, not just a legal exercise.<\/strong> The gap between the Orange Book patent expiry date and realistic generic entry \u2014 shaped by litigation timing, Paragraph IV outcomes, and 30-month stays \u2014 determines how long the reformulation’s pricing power persists. Platforms like DrugPatentWatch provide the granular data needed to assess this gap accurately, for both brand manufacturers defending their positions and payers negotiating against them.<\/p>\n\n\n\n

The $300 billion patent cliff is a reformulation opportunity at scale.<\/strong> Every major pharmaceutical company facing significant loss-of-exclusivity exposure between 2025 and 2030 is evaluating reformulation programs as part of the response. The winners in that cohort will be the companies whose reformulations earn genuine clinical premium \u2014 not the ones whose reformulations earn only a legal premium that payers and regulators will eventually erode.<\/p>\n\n\n\n

\n\n\n\n

FAQ<\/strong><\/h2>\n\n\n\n

Q1: Can a pharmaceutical company legally charge a premium for a reformulated drug that is not clinically superior to the original?<\/strong><\/p>\n\n\n\n

In the United States, pricing is not regulated by the FDA or any federal authority for commercial market products outside of Medicare negotiation. A manufacturer can charge any price it chooses for a reformulated drug, regardless of whether the clinical differentiation is genuine. The commercial constraint \u2014 not the legal one \u2014 is that payers can respond by placing the reformulation on a non-preferred formulary tier, requiring step therapy through the generic, or excluding it entirely. The legal constraint activates only if the pricing strategy is combined with conduct that courts find anticompetitive: withdrawing the original, misusing the regulatory process to block generic entry, or engaging in conduct that courts determine goes beyond the bounds of normal competition. A pure pricing premium, absent anticompetitive conduct, is not illegal.<\/p>\n\n\n\n

Q2: How does the FDA’s 505(b)(2) pathway differ from a standard generic application, and why does the distinction matter for pricing?<\/strong><\/p>\n\n\n\n

A standard generic ANDA requires a bioequivalence showing to the reference listed drug and results in an AB-rated product that pharmacists can substitute automatically. A 505(b)(2) application allows the manufacturer to rely on existing safety and efficacy data for the reference drug while making changes \u2014 to the formulation, route, dose, or indication \u2014 that justify separate approval. The result is typically a non-AB-rated product that cannot be automatically substituted. This non-substitutability is the source of the pricing power: without automatic substitution, the only market access constraint is formulary tier placement, which the manufacturer can influence through rebate negotiation. Payers retain the ability to manage the product through prior authorization and step therapy, but they cannot simply route prescriptions to a cheaper generic the way they can for AB-rated products.<\/p>\n\n\n\n

Q3: What is the most effective way for a payer to counter a manufacturer’s reformulation pricing strategy?<\/strong><\/p>\n\n\n\n

The most effective tools, in order of impact, are formulary exclusion (for reformulations without meaningful clinical differentiation, relative to a therapeutically equivalent generic), step therapy requiring documented failure on the reference generic before the reformulation is covered, outcomes-based contracting that ties manufacturer rebates to demonstrated performance in the covered population, and patent intelligence investment to accurately assess when generic entry is likely. The combination of step therapy with accurate generic entry date modeling \u2014 knowing whether the generic will arrive in 18 months or 8 years \u2014 allows the payer to calibrate how aggressively to push back on the reformulation’s price, because the commercial leverage changes substantially as generic entry probability changes.<\/p>\n\n\n\n

Q4: Is the Inflation Reduction Act’s negotiation program likely to change reformulation strategy for biologics differently than for small molecules?<\/strong><\/p>\n\n\n\n

The IRA creates a longer exemption window for biologics than for small molecules \u2014 13 years post-approval versus 9 years. This means a biologic reformulation that earns a new BLA number has 13 years of freedom from negotiation, versus 9 years for a 505(b)(2) small molecule. The longer window makes clock-reset reformulation strategy more valuable for biologics in absolute terms, but the clinical evidence requirements for biosimilar interchangeability \u2014 and the route-of-administration differentiation available in biologics that is not available in most small-molecule contexts \u2014 mean that the biologic reformulation also generates more genuine clinical differentiation than the typical small-molecule reformulation. The Keytruda Qlex situation is the best current example: the subcutaneous formulation has real clinical advantages in specific settings, earns its own new BLA approval, and resets the negotiation clock for 13 years.<\/p>\n\n\n\n

Q5: How does the FTC’s escalating enforcement against Orange Book patent listings affect a company’s reformulation IP strategy?<\/strong><\/p>\n\n\n\n

The FTC’s challenge program \u2014 which involves sending letters to manufacturers questioning specific Orange Book listings and, in some cases, filing formal complaints \u2014 has created two practical effects. First, manufacturers are reviewing their Orange Book listings with more legal scrutiny before filing, removing listings that are most vulnerable to challenge. Second, generic manufacturers who receive an FTC letter supporting the position that a particular patent is improperly listed have new leverage in their Paragraph IV certifications and district court litigation \u2014 the FTC’s position is not binding on courts but is persuasive authority. The net effect is that Orange Book listing strategies built on device or packaging patents \u2014 which are most vulnerable to the FTC’s “improper listing” theory \u2014 are less reliable as blocking mechanisms than they were in 2020. The patents that remain most durable are composition-of-matter claims on the formulation itself (specific salt forms, crystal polymorphs, excipient combinations) and method-of-treatment claims tied to specific dosing regimens with clinical data.<\/p>\n\n\n\n

\n\n\n\n

References<\/strong><\/h2>\n\n\n\n

[1] Reinhardt, S. (2003). Nexium: AstraZeneca’s successor to Prilosec and the cost to healthcare payers. Journal of Managed Care Pharmacy, 9<\/em>(4), 338\u2013344.<\/p>\n\n\n\n

[2] Arcidiacono, P., Ellickson, P., Landry, P., & Ridley, D. (2013). Pharmaceutical followers. American Economic Journal: Applied Economics<\/em>. https:\/\/doi.org\/10.3386\/w20441<\/p>\n\n\n\n

[3] Ragavan, S. (2024). Make America Healthy: Reducing High Pharmaceutical Prices Without Reducing Innovation. SMU Law Review, 77<\/em>(4), 787\u2013838.<\/p>\n\n\n\n

[4] New York ex rel. Schneiderman v. Actavis PLC (Namenda), 787 F.3d 638 (2d Cir. 2015).<\/p>\n\n\n\n

[5] Centers for Medicare & Medicaid Services. (2024). Medicare Drug Price Negotiation Program: Negotiated Prices Fact Sheet<\/em>. CMS. https:\/\/www.cms.gov\/medicare\/prescription-drug-coverage\/negotiating-drug-prices<\/p>\n\n\n\n

[6] DrugPatentWatch. (2025, March). The complete architecture of pharmaceutical drug pricing: Patents, power, and the post-IRA market<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/deconstructing-drug-pricing-strategy-for-big-pharma\/<\/p>\n\n\n\n

[7] DrugPatentWatch. (2025, October). Strategic pricing and market access for 505(b)(2) therapeutics: A framework for optimal launch<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/strategic-pricing-and-market-access-for-505b2-therapeutics-a-framework-for-optimal-launch\/<\/p>\n\n\n\n

[8] DrugPatentWatch. (2025, November). What is drug product hopping: A deep dive<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/what-is-drug-product-hopping-a-deep-dive-into-drug-product-hopping-and-its-impact-on-the-pharmaceutical-industry\/<\/p>\n\n\n\n

[9] DrugPatentWatch. (2026, March). Does drug patent evergreening prevent generic entry?<\/em> https:\/\/www.drugpatentwatch.com\/blog\/does-drug-patent-evergreening-prevent-generic-entry\/<\/p>\n\n\n\n

[10] DrugPatentWatch. (2026, March). The 505(b)(2) goldmine: How pharma extracts maximum IP value from modified drugs<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/review-of-drugs-approved-via-the-505b2-pathway-uncovering-drug-development-trends-and-regulatory-requirements-2\/<\/p>\n\n\n\n

[11] Hemphill, C. S., & Lemley, M. A. (2016). Earning exclusivity: Generic drug incentives and the Hatch-Waxman Act. Antitrust Law Journal, 78<\/em>(3), 947\u2013989.<\/p>\n\n\n\n

[12] Health Affairs Forefront. (2016). Pharmaceutical product hopping: A proposed framework for antitrust analysis<\/em>. https:\/\/www.healthaffairs.org\/content\/forefront\/pharmaceutical-product-hopping-proposed-framework-antitrust-analysis<\/p>\n\n\n\n

[13] Health Affairs Forefront. (2018). A preferable path for thwarting pharmaceutical product hopping<\/em>. https:\/\/www.healthaffairs.org\/do\/10.1377\/hblog20180522.408497\/full\/<\/p>\n\n\n\n

[14] Choudhry, N. K., et al. (2023). Drug lifecycle management as anticompetitive behavior: The case of memantine. PMC\/NCBI<\/em>. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10398055\/<\/p>\n\n\n\n

[15] Carrier, M. A., & Mograbi, S. (2020). Brand drug product hopping costs U.S. $4.7B annually. TechTarget\/SearchHealthIT<\/em>. https:\/\/www.techtarget.com\/pharmalifesciences\/news\/366607539\/Brand-Drug-Product-Hopping-Costs-US-47B-Annually<\/p>\n\n\n\n

[16] FREOPP. (2025). How drug companies stifle competition with ‘product hopping.’<\/em> https:\/\/freopp.org\/oppblog\/how-drug-companies-stifle-competition-with-product-hopping\/<\/p>\n\n\n\n

[17] Edgeworth Economics. (2024). Product hopping common considerations.<\/em> https:\/\/www.edgewortheconomics.com\/publication-product-hopping-pharma<\/p>\n\n\n\n

[18] BioPharma Dive. (2025, October 2). Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?<\/em> https:\/\/www.biopharmadive.com\/news\/merck-keytruda-subcutaneous-cancer-sales-drug-delivery\/801889\/<\/p>\n\n\n\n

[19] CSRxP. (2025, January). Big Pharma watch: Merck expedites anti-competitive strategy on blockbuster cancer drug.<\/em> https:\/\/www.csrxp.org\/big-pharma-watch-merck-expedites-anti-competitive-strategy-on-blockbuster-cancer-drug\/<\/p>\n\n\n\n

[20] DeepCeutix. (2026, February). $300 billion in pharma revenue loses patent protection by 2030.<\/em> https:\/\/deepceutix.com\/insights\/patent-cliff-reformulation<\/p>\n\n\n\n

[21] I-MAK. (2025). The heavy price of GLP-1 drugs: How financialization drives pharmaceutical patent abuse and health inequities.<\/em> https:\/\/www.i-mak.org\/glp-1\/<\/p>\n\n\n\n

[22] Markman Advisors. (2025, February). What is the patent landscape for Novo Nordisk’s semaglutide products?<\/em> https:\/\/www.markmanadvisors.com\/blog\/2025\/2\/7\/what-is-the-patent-landscape-for-novo-nordisks-semaglutide-products-ozempic-wegovy-and-rybelsus<\/p>\n\n\n\n

[23] MLex. (2026). Semaglutide patent expiry exposes global split on access, exclusivity.<\/em> https:\/\/www.mlex.com\/mlex\/articles\/2459669\/semaglutide-patent-expiry-exposes-global-split-on-access-exclusivity<\/p>\n\n\n\n

[24] HCPLive. (2026, April). Novo Nordisk announces 2027 price reduction of Wegovy, Ozempic, Rybelsus.<\/em> https:\/\/www.hcplive.com\/view\/novo-nordisk-announces-2027-price-reduction-of-wegovy-ozempic-rybelsus<\/p>\n\n\n\n

[25] PharmExec. (2026, April). The new era of U.S. pharmaceutical pricing: From policy upheaval to strategic adaptation.<\/em> https:\/\/www.pharmexec.com\/view\/pharmaceutical-pricing-policy-strategic-adaptation<\/p>\n\n\n\n

[26] MedPath. (2025, November). FDA 505(b)(2) pathway drives 69 drug reformulations in 2024-2025.<\/em> https:\/\/trial.medpath.com\/news\/2c86f6856832466d\/fda-505-b-2-pathway-drives-69-drug-reformulations-in-2024-2025-focusing-on-stability-and-patient-experience<\/p>\n\n\n\n

[27] AMCP Foundation. (2024). Emerging trends in pharmaceutical payment models: Perspectives on the 2024 AMCP Foundation Survey<\/em>. PMC<\/em>. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11785357\/<\/p>\n\n\n\n

[28] PNAS. (2025). Policy options for the drug pricing conundrum.<\/em> https:\/\/www.pnas.org\/doi\/10.1073\/pnas.2418540122<\/p>\n\n\n\n

[29] Pharmacy Times. (2026). Understanding recent changes to 505(b)(2) drugs and reimbursement.<\/em> https:\/\/www.pharmacytimes.com\/view\/understanding-recent-changes-to-505-b-2-drugs-and-reimbursement<\/p>\n\n\n\n

[30] Ventola, C. L. (2013). Biosimilars: Part 1: Proposed regulatory criteria for FDA approval. P&T, 38<\/em>(5), 270\u2013287.<\/p>\n","protected":false},"excerpt":{"rendered":"

The molecule did not change. The price did. When AstraZeneca introduced esomeprazole \u2014 branded as Nexium \u2014 in 2001, it […]<\/p>\n","protected":false},"author":1,"featured_media":38573,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-38565","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=38565"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38565\/revisions"}],"predecessor-version":[{"id":38574,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38565\/revisions\/38574"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/38573"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=38565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=38565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=38565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}